Herein, we reported that up-regulated CSNK2B expression can result in activation of mTOR and its downstream effectors p70S6K and 4E-BP1, and inhibition of mTOR activity by rapamycin treatment significantly abolished the positive effects of CSNK2B on CRC cell viability. The gene discussed is EIF4EBP1; the disease is colorectal carcinoma.